CN102245185A - 胰岛素与三嗪衍生物的组合及其用于治疗糖尿病的应用 - Google Patents
胰岛素与三嗪衍生物的组合及其用于治疗糖尿病的应用 Download PDFInfo
- Publication number
- CN102245185A CN102245185A CN2009801495028A CN200980149502A CN102245185A CN 102245185 A CN102245185 A CN 102245185A CN 2009801495028 A CN2009801495028 A CN 2009801495028A CN 200980149502 A CN200980149502 A CN 200980149502A CN 102245185 A CN102245185 A CN 102245185A
- Authority
- CN
- China
- Prior art keywords
- insulin
- chemical compound
- formula
- meant
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*)(N=C(N1)N(*)*)N=C1N(*)* Chemical compound CC(*)(N=C(N1)N(*)*)N=C1N(*)* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
天 | 0 | 8 | 15 | 22 | 36 |
对照 | 57 | 653 | 597 | 496 | 459 |
sem | 12 | 76 | 59 | 29 | 56 |
EMD 75mg/kg | 63 | 666 | 602 | 592 | 475 |
sem | 11 | 93 | 62 | 80 | 81 |
EMD 150mg/kg | 48 | 586 | 635 | 558 | 496 |
sem | 8 | 82 | 77 | 39 | 50 |
分钟 | 0 | 10 | 20 | 30 | 45 | 60 | 90 | 120 |
对照胰岛素 | 21,46 | 22,73 | 26,98 | 27,83 | 28,04 | 25,59 | 20,35 | 16,91 |
sem | 3,10 | 2,85 | 2,97 | 2,86 | 3,43 | 3,05 | 2,77 | 2,43 |
胰岛素+EMD 75 | 18,86 | 20,27 | 24,33 | 25,16 | 24,53 | 22,38 | 19,41 | 16,36 |
sem | 2,77 | 2,49 | 2,60 | 2,71 | 2,74 | 2,48 | 2,68 | 2,35 |
胰岛素+EMD 150mg/kg | 16,29 | 17,43 | 21,30 | 22,21 | 22,90 | 20,37 | 17,82 | 14,85 |
sem | 2,35 | 1,80 | 1,98 | 1,88 | 2,21 | 2,43 | 2,30 | 2,05 |
mg | % | |
5,6-二氢-4-二甲基氨基-2-亚氨基-6-甲基-1,3,5-三嗪 | 200 | 87.0 |
乳糖 | 10.5 | 4.6 |
淀粉 | 5.7 | 2.5 |
交聚维酮 | 5.7 | 2.5 |
滑石粉 | 7 | 3.0 |
硬脂酸镁 | 1.1 | 0.5 |
总计 | 230 | 100.0 |
Mg | % | |
5,6-二氢-4-二甲基氨基-2-亚氨基-6-甲基-1,3,5-三嗪 | 100 | 43.5 |
甘露醇 | 50.5 | 22.0 |
艾维素(Avicel)ph 102 | 60 | 26.1 |
羟丙纤维素 | 5.7 | 2.5 |
淀粉 | 5.7 | 2.5 |
滑石粉 | 7 | 3.0 |
硬脂酸镁 | 1.1 | 0.5 |
总计 | 230 | 100.0 |
Mg | % | |
5,6-二氢-4-二甲基氨基-2-亚氨基-6-甲基-1,3,5-三嗪 | 50 | 21.7 |
甘露醇 | 80.5 | 35.0 |
艾维素ph102 | 80 | 34.8 |
羟丙纤维素 | 5.7 | 2.5 |
淀粉 | 5.7 | 2.5 |
滑石粉 | 7 | 3.0 |
硬脂酸镁 | 1.1 | 0.5 |
总计 | 230 | 100.0 |
mg | % | |
5,6-二氢-4-二甲基氨基-2-亚氨基-6-甲基-1,3,5-三嗪 | 200 | 87.0 |
甘露醇 | 10.5 | 4.6 |
羟丙纤维素 | 5.7 | 2.5 |
淀粉 | 5.7 | 2.5 |
滑石粉 | 7 | 3.0 |
硬脂酸镁 | 1.1 | 0.5 |
总计 | 230 | 100.0 |
mg | % | |
5,6-二氢-4-二甲基氨基-2-亚氨基-6-甲基-1,3,5-三嗪 | 100 | 79.4 |
乳糖 | 12.2 | 9.7 |
羟丙纤维素 | 5.7 | 4.5 |
滑石粉 | 7 | 5.6 |
硬脂酸镁 | 1.1 | 0.9 |
总计 | 126 | 100.0 |
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08021617.9 | 2008-12-12 | ||
EP08021617 | 2008-12-12 | ||
PCT/EP2009/008099 WO2010066326A1 (en) | 2008-12-12 | 2009-11-13 | Combination of insulin with triazine derivatives and its use for treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102245185A true CN102245185A (zh) | 2011-11-16 |
Family
ID=41566311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801495028A Pending CN102245185A (zh) | 2008-12-12 | 2009-11-13 | 胰岛素与三嗪衍生物的组合及其用于治疗糖尿病的应用 |
Country Status (23)
Country | Link |
---|---|
US (2) | US8592370B2 (zh) |
EP (1) | EP2355829B1 (zh) |
JP (1) | JP5667985B2 (zh) |
KR (1) | KR101623819B1 (zh) |
CN (1) | CN102245185A (zh) |
AR (1) | AR074555A1 (zh) |
AU (1) | AU2009326604B2 (zh) |
BR (1) | BRPI0923373B8 (zh) |
CA (1) | CA2746479C (zh) |
CY (1) | CY1115973T1 (zh) |
DK (1) | DK2355829T3 (zh) |
EA (1) | EA021395B1 (zh) |
ES (1) | ES2530223T3 (zh) |
HR (1) | HRP20150064T1 (zh) |
IL (1) | IL213421A (zh) |
MX (1) | MX2011006073A (zh) |
PL (1) | PL2355829T3 (zh) |
PT (1) | PT2355829E (zh) |
SG (1) | SG171986A1 (zh) |
SI (1) | SI2355829T1 (zh) |
SM (1) | SMT201500032B (zh) |
WO (1) | WO2010066326A1 (zh) |
ZA (1) | ZA201105094B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112218623A (zh) * | 2018-06-14 | 2021-01-12 | 博希尔公司 | 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2577930T3 (es) * | 2010-06-09 | 2016-07-19 | Poxel | Derivados de triazina para retrasar el inicio de la diabetes tipo 1 |
TWI436768B (zh) * | 2010-06-09 | 2014-05-11 | Poxel | 第2型糖尿病之治療 |
SG10201604828QA (en) * | 2011-12-12 | 2016-07-28 | Melior Pharmaceuticals I Inc | Treatment Of Type I And Type II Diabetes |
KR20200102982A (ko) | 2017-10-02 | 2020-09-01 | 폭셀 | 보존된 박출률을 갖는 심부전의 치료 방법 |
TW202015696A (zh) | 2018-06-06 | 2020-05-01 | 瑞士商梅萬特科學公司 | 治療患有慢性腎臟病之糖尿病患者之方法 |
JP7093473B2 (ja) * | 2019-12-13 | 2022-06-29 | 住友ファーマ株式会社 | 製造性及び溶出性に優れた小型錠剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3172814A (en) * | 1962-04-06 | 1965-03-09 | Jr Edgar A Ferguson | Oral blood sugar lowering compositions |
FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
WO2002060422A2 (en) * | 2001-02-02 | 2002-08-08 | Pfizer Limited | Treatment of diabetes mellitus using vardenafil |
DE10301788B4 (de) * | 2003-01-20 | 2005-08-25 | Aventis Pharma Deutschland Gmbh | Pharmazeutische Verwendung von Pyrimido[5,4-e][1,2,4]triazin-5,7-dionen |
FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
FR2896159B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
-
2009
- 2009-11-13 WO PCT/EP2009/008099 patent/WO2010066326A1/en active Application Filing
- 2009-11-13 DK DK09756258.1T patent/DK2355829T3/en active
- 2009-11-13 ES ES09756258.1T patent/ES2530223T3/es active Active
- 2009-11-13 SI SI200931123T patent/SI2355829T1/sl unknown
- 2009-11-13 AU AU2009326604A patent/AU2009326604B2/en not_active Ceased
- 2009-11-13 CN CN2009801495028A patent/CN102245185A/zh active Pending
- 2009-11-13 KR KR1020117016022A patent/KR101623819B1/ko active IP Right Grant
- 2009-11-13 EA EA201100916A patent/EA021395B1/ru not_active IP Right Cessation
- 2009-11-13 MX MX2011006073A patent/MX2011006073A/es active IP Right Grant
- 2009-11-13 SG SG2011041175A patent/SG171986A1/en unknown
- 2009-11-13 US US13/139,027 patent/US8592370B2/en active Active
- 2009-11-13 CA CA2746479A patent/CA2746479C/en active Active
- 2009-11-13 JP JP2011539914A patent/JP5667985B2/ja active Active
- 2009-11-13 BR BRPI0923373A patent/BRPI0923373B8/pt active IP Right Grant
- 2009-11-13 EP EP09756258.1A patent/EP2355829B1/en active Active
- 2009-11-13 PL PL09756258T patent/PL2355829T3/pl unknown
- 2009-11-13 PT PT97562581T patent/PT2355829E/pt unknown
- 2009-12-09 AR ARP090104757A patent/AR074555A1/es unknown
-
2011
- 2011-06-06 IL IL213421A patent/IL213421A/en active IP Right Grant
- 2011-07-11 ZA ZA2011/05094A patent/ZA201105094B/en unknown
-
2013
- 2013-07-15 US US13/941,677 patent/US8980828B2/en active Active
-
2015
- 2015-01-19 HR HRP20150064AT patent/HRP20150064T1/hr unknown
- 2015-01-30 CY CY20151100101T patent/CY1115973T1/el unknown
- 2015-02-11 SM SM201500032T patent/SMT201500032B/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112218623A (zh) * | 2018-06-14 | 2021-01-12 | 博希尔公司 | 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102245185A (zh) | 胰岛素与三嗪衍生物的组合及其用于治疗糖尿病的应用 | |
ES2573266T3 (es) | Compuestos de tetrahidrotriazina para tratar enfermedades relacionadas con la actividad de AMPK | |
CA2534314C (en) | Benzothiazole derivatives for the treatment of diabetes | |
CN102316872A (zh) | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 | |
AU2015331074B2 (en) | Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | |
US20170065608A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
WO2012041898A1 (en) | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes | |
WO2018079149A1 (ja) | 白内障の予防剤、治療剤、およびこれらを製造するためのhat阻害剤の使用 | |
CN104582704A (zh) | 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物 | |
CN104271140B (zh) | I型和ii型糖尿病的治疗 | |
CN113679728B (zh) | 一种磺胺类化合物及其在制备治疗糖尿病和并发症药物中的应用 | |
CN111195247B (zh) | 一种α-葡萄糖苷酶抑制剂及其在降血糖药物中的应用 | |
WO2024109153A1 (zh) | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 | |
CN110169969B (zh) | Mk571在制备预防和治疗心脏病药物中应用 | |
CN101735218A (zh) | 哌啶氨基甲酸酯衍生物及其应用 | |
CN101801373B (zh) | 具有抗糖尿病作用的药物组合物 | |
CN100378090C (zh) | 取代的二氧戊环衍生物及其用于制备神经调节剂的用途 | |
CN100382793C (zh) | (e) -4,4′-二甲氧基苯乙烯的新用途及含有其的组合物 | |
CN109293644A (zh) | 6-甲基烟酸甲酯在制备na抑制剂中的应用 | |
WO2015134357A1 (en) | Modulators of insulin receptor | |
CN113679725A (zh) | 一种头孢类化合物及其在制备治疗糖尿病和并发症药物中的应用 | |
CN110467624A (zh) | 一类黄烷与二苯乙烯类化合物骈合而成的加合物 | |
CN103285020A (zh) | 甘草酸在制备减轻马来酸苏尼替尼心脏毒性药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1164128 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BOKSAIRE COMPANY Free format text: FORMER OWNER: MERCK PATENT GMBH Effective date: 20121116 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20121116 Address after: lyon Applicant after: Polk Zale Corporation Address before: Darmstadt Applicant before: Merck Patent GmbH |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20111116 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1164128 Country of ref document: HK |